NextCure (NASDAQ:NXTC) Stock: Insider Adar1 Capital Management, Llc Buys 3,553 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 3,553 shares of the stock in a transaction dated Tuesday, October 27th. The stock was bought at an average price of $5.10 per share, with a total value of $18,120.30. Following the acquisition, the insider owned 733,270 shares in the company, valued at approximately $3,739,677. This represents a 0.49% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, October 26th, Adar1 Capital Management, Llc bought 1,672 shares of NextCure stock. The stock was bought at an average cost of $5.03 per share, for a total transaction of $8,410.16.
• On Friday, October 23rd, Adar1 Capital Management, Llc purchased 5,626 shares of NextCure stock. The shares were bought at an average price of $4.83 per share, for a total transaction of $27,173.58.
• On Friday, July 31st, Adar1 Capital Management, Llc purchased 36,303 shares of NextCure stock. The shares were bought at an average price of $4.94 per share, for a total transaction of $179,336.82.
• On Thursday, July 30th, Adar1 Capital Management, Llc purchased 292,850 shares of NextCure stock. The stock was bought at an average cost of $4.93 per share, with a total value of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The stock was bought at an average cost of $5.00 per share, with a total value of $17,050.00.

NextCure Price Performance

NASDAQ NXTC opened at $6.34 on Thursday. NextCure, Inc. has a 1 year low of $1.55 and a 1 year high of $15.74. The company has a market capitalization of $22.89 million, a PE ratio of -0.73 and a beta of 1.33. The company has a fifty day moving average of $6.10 and a two-hundred day moving average of $7.96.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Institutional Inflows and Outflows

A hedge fund recently raised its position in NextCure stock. Renaissance Technologies LLC grew its position in NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,534 shares of the company’s stock after acquiring an additional 26,900 shares during the period. Renaissance Technologies LLC owned about 1.68% of NextCure worth $647,000 at the end of the most recent quarter. 42.65% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

NXTC has been the topic of a number of research reports. HC Wainwright restated a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. Wall Street Zen upgraded NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.00.

NextCure Company Profile

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.